Canada markets open in 6 hours 2 minutes

RepliCel Life Sciences Inc. (RP.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.4100+0.0500 (+13.89%)
At close: 3:50PM EST
Full screen
Previous Close0.3600
Open0.3950
Bid0.3700 x 0
Ask0.4200 x 0
Day's Range0.3950 - 0.4100
52 Week Range0.1000 - 0.5800
Volume12,505
Avg. Volume52,798
Market Cap14.043M
Beta (5Y Monthly)0.84
PE Ratio (TTM)N/A
EPS (TTM)-0.0650
Earnings DateNov. 27, 2015 - Nov. 30, 2015
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • RepliCel Presents Its Technology Development and Commercialization Plans for Japan at Kanagawa Regenerative Medicine Industry Conference
    ACCESSWIRE

    RepliCel Presents Its Technology Development and Commercialization Plans for Japan at Kanagawa Regenerative Medicine Industry Conference

    Kanagawa Regeneration and Cell Medical Industry Network Organizers Invite RepliCel to Participate in Foreign Company Pitch SessionVANCOUVER, BC / ACCESSWIRE /February 18, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced its President and CEO, R.

  • RepliCel Closes First Tranche of Strategic Investment Commitment
    ACCESSWIRE

    RepliCel Closes First Tranche of Strategic Investment Commitment

    MainPointe Pharmaceuticals Completes Initial Share Purchase per Investment AgreementVANCOUVER, BC / ACCESSWIRE / February 10, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has closed the first tranche of the investment by MainPointe Pharmaceuticals ("MainPointe") as outlined in the share purchase agreement signed earlier this year by the parties.

  • ACCESSWIRE

    RepliCel CEO Provides Corporate Update

    Targets for 2021 include dermal injector commercial launch, new partnerships, new innovation initiatives, and launch of more clinical testing VANCOUVER, BC / ACCESSWIRE / February 8, 2021 / RepliCel Life Sciences Inc. (TSXV:RP)(OTC PINK:REPCF)(FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to provide an update to shareholders from its Board and Management represented by President and CEO, Mr.